Establishment Labs (ESTA) Expected to Post Earnings on Thursday

Establishment Labs (NASDAQ:ESTA) is expected to release its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect Establishment Labs to post earnings of ($0.34) per share and revenue of $65.7910 million for the quarter. Parties can check the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, August 6, 2026 at 8:30 AM ET.

Establishment Labs (NASDAQ:ESTA) last posted its earnings results on Thursday, May 7th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.10). The company had revenue of $59.88 million for the quarter, compared to the consensus estimate of $57.40 million. Establishment Labs had a negative net margin of 19.05% and a negative return on equity of 218.77%. The firm’s revenue for the quarter was up 44.7% compared to the same quarter last year. During the same period last year, the company posted ($0.70) earnings per share. On average, analysts expect Establishment Labs to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Establishment Labs Trading Up 0.0%

Shares of NASDAQ ESTA opened at $91.93 on Thursday. Establishment Labs has a 12-month low of $33.35 and a 12-month high of $96.99. The company has a market cap of $2.71 billion, a price-to-earnings ratio of -61.70 and a beta of 1.06. The company has a current ratio of 2.96, a quick ratio of 1.91 and a debt-to-equity ratio of 16.82. The stock’s 50 day simple moving average is $84.07 and its 200 day simple moving average is $73.22.

Wall Street Analyst Weigh In

Several research firms have recently commented on ESTA. TD Cowen restated a “buy” rating on shares of Establishment Labs in a research report on Monday, June 8th. Weiss Ratings reissued a “sell (e+)” rating on shares of Establishment Labs in a research note on Wednesday, June 24th. Mizuho upped their target price on shares of Establishment Labs from $100.00 to $105.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 15th. Citigroup raised their price target on shares of Establishment Labs from $76.00 to $92.00 and gave the company a “neutral” rating in a research note on Wednesday, July 8th. Finally, BTIG Research reaffirmed a “buy” rating on shares of Establishment Labs in a report on Monday, July 13th. Seven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $90.43.

Insider Activity

In related news, Director Quiros Juan Jose Chacon sold 105,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 6th. The shares were sold at an average price of $75.42, for a total transaction of $7,919,100.00. Following the transaction, the director owned 927,504 shares in the company, valued at $69,952,351.68. This trade represents a 10.17% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold 180,000 shares of company stock valued at $13,225,275 in the last ninety days. Company insiders own 9.99% of the company’s stock.

Hedge Funds Weigh In On Establishment Labs

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ESTA. Geode Capital Management LLC increased its position in shares of Establishment Labs by 1.2% during the 2nd quarter. Geode Capital Management LLC now owns 25,917 shares of the company’s stock valued at $1,105,000 after purchasing an additional 299 shares during the period. Swiss National Bank lifted its holdings in shares of Establishment Labs by 1.8% in the fourth quarter. Swiss National Bank now owns 34,200 shares of the company’s stock valued at $2,492,000 after buying an additional 600 shares during the period. Kestra Advisory Services LLC acquired a new stake in shares of Establishment Labs in the fourth quarter valued at $47,000. Private Advisor Group LLC boosted its stake in Establishment Labs by 14.1% during the third quarter. Private Advisor Group LLC now owns 5,450 shares of the company’s stock valued at $223,000 after buying an additional 675 shares in the last quarter. Finally, Quarry LP bought a new position in Establishment Labs during the third quarter valued at about $34,000. 72.91% of the stock is owned by institutional investors.

Establishment Labs Company Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.